RC-12 [1,2-dimethoxy-4-(bis-diethylaminoethyl)-amino-5-bromobenzeneI was evaluated for prophylactic, radical curative, and suppressive activities against infections with Plasmodium cynomolgi and subacute toxicity in rhesus monkeys. Applied as a prophylactic agent, RC-12, administered in doses of 6.25 to 25.0 mg/kg daily throughout the incubation period, provided near-complete to complete protection against 105 to 106 times the minimum infective dose of sporozoites. Applied as a suppressive agent, daily doses of 100.0 mg of RC-12 per kg did not eradicate blood schizonts regularly; hence, the need for concomitant administration of a blood schizonticide, such as chloroquine, in assessments of radical curative activity. In such appraisals, daily doses of 6.25 to 25.0 mg of RC-12 per kg for 14 days, in combination with 2.5 mg of chloroquine per kg daily for 7 days, effected cure of 69 and 93% of established infections, respectively. The curative activity of RC-12 was related to the total dose and could be achieved with a regimen as brief as 4 days. With respect to outward expressions of toxicity, daily doses of 50.0 mg/kg or lower for 15 to 225 days evoked no reactions. Doses of 100.0 or 200.0 mg/kg, scheduled for 15 days, evoked convulsions and depression and were, respectively, lethal to 4 of 17 and 7 of 7 recipients. Doses of 25.0 mg/kg or lower evoked no discrete reactions. Doses of 50.0 mg/kg and higher evoked hepatomegaly, vacuolation of hepatocytes, and elevations of glutamic oxalacetic and glutamic pyruvic transferase activities in serum, reactions related in intensity to dose but not duration of dosage.
RC-12 [1,2-dimethoxy-4-(bis-diethylaminoethyl)-amino-5-
. Shortly thereafter, Dimeplasmin was evaluated for activity against both blood-induced and naturally acquired infections with Plasmodium falciparum and Plasmodiiiin Oii'ax, where it proved to be less effective than quinine in controlling parasitemia (11, 12, 43 ; personal communications to W.S. from Muhlens, 1928, and Sioli, 1929) . At that point, those involved in these studies turned attention to the newly prepared Atebrin (quinacrine) (18) .
In 1946, two of the authors of this report (W.S., who had been a major participant in the 1926 studies, and L.K.) undertook a reinvestigation of the antimalarial properties of the 4-amino-substituted pyrocatechols. This renewed interest stemmed from the attention then being given to the development of antimalarial drugs with capacity for radical * A total of 306 juvenile, subadult, and young adult feral rhesus monkeys (Macaca mulatta), imported directly from New Delhi, India, were used in these studies: 217 for assessments of antimalarial activity and 89 for evaluations of toxicity. The assignees to each of these investigations included approximately equal numbers of males and females. At the time of assignment to an experiment, 94 of the 306 monkeys weighed between 2.3 and 2.9 kg, 147 weighed between 3.0 and 3.9 kg, 56 weighed between 4.0 and 4.9 kg, and 9 weighed between 5.2 and 7.4 kg. The procedures for acquiring these monkeys, transporting them from New Delhi to Davis, Calif., and conditioning them for experimental use, routine colony husbandry practices (including dietary management), and methods of handling for all facets of the studies without resort to sedatives, tranquilizers, anesthetics, or squeeze cages were identical with those described previously (33, 35, 37) .
Assessments of prophylactic, radical curative, and suppressive activities. The B and RolPM (pyrimethamine-resistant) strains of P. cynomolgi were used in these studies. The latter strain served a single assessment of prophylactic activity, and the B strain served all other assessments of prophylactic activity and all assessments of radical curative and suppressive activities. The origins of these strains, their maintenance via serial monkey-to-mosquito-to-monkey passages, the characteristics of untreated sporozoite-induced and trophozoite-induced infections, and the responses of such infections to standard blood and tissue schizonticidal drugs have been detailed previously (35, 36, 39) . The evaluations of prophylactic and radical curative activities were carried out on monkeys inoculated intravenously with 7.9 x 104 to 1.2 x 106 sporozoites derived from the ground thoraces of Anopheles freeborni with heavily infected salivary glands. The procedures used to acquire lots of well-infected mosquitoes, monitor development of gut and salivary gland infections, harvest sporozoites from ground mosquito thoraces, and enumerate numbers of sporozoites in the inoculum were identical with those described elsewhere (38) . Evaluations of suppressive activity were carried out on monkeys inoculated intravenously with 5 x 105 trophozoites derived from the blood of an untreated monkey in the serial monkey-to-mosquito-to-monkey passage line uling smear preparations, were identical with those detailed previously for comparable evaluations of other agents (36) . The criteria employed in these studies for full protection against sporozoite challenge (prophylaxis), radical cure, and suppressive cure were identical with those described and validated elsewhere (36) . In brief, the yardstick for prophylaxis was either full susceptibility to rechallenge with sporozoites, carried out 60 or more parasite-free days after the initial challenge, or absence of parasitemia for 76 or more days after challenge, including at least 21 days after splenectomy. The criterion for radical cure was the absence of parasitemia for 21 or more days after splenectomy which had been performed 60 or more thick-blood-film-negative days after delivery of the last dose of RC-12 or other agent to a monkey with an established sporozoite-induced infection. The yardstick for suppressive cure was the absence of parasitemia for a minimum of 60 days after administration of the last dose of test agent to a monkey with an established trophozoite-induced infection.
Assessments of toxicity. These evaluations included a very limited study of the acute oral toxicity of RC-12 and five relatively substantial studies of the subacute oral toxicity of this compound. In four of the five assessments, RC-12 was administered for 15 to 17 days; in one, it was administered for 225 days. The shorter studies dealt with the toxicity of RC-12 acetate administered alone, the impacts of concomitant administration of chloroquine on the toxicity of this salt, and the comparative toxicities of RC-12 acetate and RC-12 NDS. The longer study dealt only with the toxicity of RC-12 NDS.
In all of the subacute toxicity studies, monkeys were followed closely for evidences of impaired hematopoietic provided full protection to 9 of 10 monkeys ( Table 1) .
The second of the supplemental studies was designed to determine for how long after the last of nine consecutive daily doses of RC-12 monkeys were protected against sporozoite challenge. This indirect assessment of the persistence of RC-12 was made necessary by the lack of a satisfactory procedure for measuring the concentrations of this agent and possibly its active metabolites in body fluids and tissues. A total of 24 monkeys, divided into six equally sized groups, were committed to this experiment. Included were a group of untreated controls and five groups of treated monkeys, the latter groups being dosed daily with RC-12 for 9 days on a staggered schedule such that all could be challenged at the same time but on either the day of the last dose or 2, 4, 6, or 8 days thereafter. Two monkeys in each group received doses of 12.5 mg/kg, and two received doses of 50.0 mg/kg administered as the NDS. The lower of these doses was selected because it was midway between the nearly fully effective and the fully effective doses of 6.25 and 25.0 mg/kg ( Table 1 ). The larger dose was selected because it was double the fully effective dose.
The results of this experiment show that one of the two recipients of the 12.5-mg/kg dose, challenged on the last day schizonts and that altogether the initial treatment with RC-12 had eradicated the tissue schizonts (the essential requirement for radical cure) in seven of the nine recipients of 25.0-mg/kg doses and in six of six recipients of 100.0-mg/kg doses. The results of this experiment made it necessary to assess the activity of RC-12 against infections with trophozoites. This assessment, although not in the radical cure category, is described here because it produced results that determined the design of subsequent appraisals of radical curative activity. The experiment involved work with a group of 13 monkeys, each inoculated with 5 x 105 trophozoites of the B strain; 1 served as an untreated control and the remaining 12, in subgroups of 3, received RC-12 in doses of 1.56, 6.25, 25.0, and 100.0 mg/kg once daily for 7 consecutive days. Treatment with these doses was initiated in the ascending phase of the primary attack when 10 to 40 of each 104 erythrocytes were parasitized. When parasitemias persisted or reappeared after apparent clearance, second and, if required, third courses at higher doses were applied, except for infections originally treated with 100.0 mg of RC-12 per kg, concerns with toxicity precluding dosage above that level.
The results of this experiment, covering a total of 24 treatment courses, showed that doses of RC-12 ranging from 6.25 to 100.0 mg/kg regularly reduced parasitemias to the thick-blood-film-negative level. In most subjects, this reduction took place within 6 days of the first dose, but with three exceptions, one in a first retreatment course and two in a second, doses of RC-12 failed to eradicate all parasites ( Table 6 ). Doses of 1.56 mg/kg suppressed parasitemia significantly but did not effect clearance. These results, showing that RC-12 had significant activity against blood schizonts but could not be depended upon for eradication of these forms, led to the concomitant administration of chloroquine in all subsequent assessments of the radical curative activity of this pyrocatechol.
The second major study of the curative activity of RC-12 was concerned with the capacity of this agent to eradicate established sporozoite-induced infections when administered as either the acetate or the NDS salt concomitantly with chloroquine. The 57 monkeys committed to this evaluation included 43 with previously untreated infections; 18 were inoculated for assessment of the activity of the acetate salt, and 25 were inoculated for a comparison of the activities of the acetate and NDS salts. Of the remaining 14 monkeys, 8 were derived from assessments of the prophylactic activity of RC-12 and had been treated with either this agent or chloroquine during the primary attack or first relapse. The remaining six monkeys had served an assessment of the prophylactic and curative activity of the 6-aminoquinoline B-505, with entirely negative results (31) . In the test for cure, RC-12 was administered once daily for 14 days in doses ranging from 0.39 to 100.0 mg/kg concomitantly with chloroquine in daily doses of 2.5 mg/kg for the first 7 days. The 14-day schedule for RC-12 was the counterpart of the conventional primaquine treatment regimen. The 7-day schedule for chloroquine was one that has been shown to be completely effective in eradicating infections with trophozoites of the B strain (36) . Treatment of previously untreated infections was initiated early in the primary attack, when parasitemias involved from 10 to 40 of each 104 erythrocytes. Treatment of relapses, whether in the special group of monkeys or in those receiving RC-12 in the primary attack, was initiated within 3 days of reestablishment of patency.
At daily doses of 0.39 and 1.56 mg/kg, RC-12 showed no evidence of curative activity (Table 7) . In contrast, delivery of doses of 6.25 and 25.0 mg/kg effected cure of 22 24 h. Thereafter, his behavior in his cage and upon release into the cage room was entirely normal. Limited as they were, these results guided the selection of doses for both the initial appraisals of prophylactic and radical curative activities and the first of the repetitive-dose toxicity evaluations.
(ii) Subacute toxicity. The untoward reactions evoked by repeated daily doses of RC-12 were studied in five separate experiments, four of common design. The first two of these four, carried out with RC-12 acetate, were designed: (i) to identify the types of reactions evoked by RC-12 and the dose level at which these reactions occurred; (ii) to determine whether the concomitant administration of chloroquine modified the toxicity of RC-12 either qualitatively or quantitatively; and (iii) to provide the basis for developing a crude therapeutic index. These experiments, each lasting 15 days, were served by 25 monkeys; 14 30 March 1967), showed that there was a loss of the usual green color and deposition of fine black pigment in the tapetum lucidum of six of six dogs given daily doses of 80.0 mg of RC-12 per kg for 11 weeks and one of six dogs given doses of 40.0 mg/kg for that period. Although the rhesus monkey does not have a tapetum lucidum, earlier experiences on the ocular toxicity of ethambutol (28) suggested that the observations on the canine eye should not be ignored and that the impacts of RC-12 on structure and function of the simian eye deserved attention.
The resulting long-term study, originally planned as a 180-day experiment, was extended to 225 days because of the absence of key personnel on the scheduled termination date. It was served by 20 monkeys; 5 served as untreated controls and three groups of 5 were given RC-12 in daily doses of 12.5, 25.0, and 50.0 mg/kg. Reference should be made to the Materials and Methods section for all experimental procedures employed in this experiment, except those pertinent to disturbances in visual function. The latter were performed on both treated and control monkeys twice before the start of the experiment and once every 2 weeks thereafter. At these times, animals were subjected to a careful ophthalmoscopic examination while being gently restrained in a sitting position by an animal caretaker. The monkeys were then placed in a restraining chair with head held firmly but with arms free to push away a 2-mm-diameter dowel stick as it was moved toward the orbit from various angles. After this test, the monkey was set free in a caged area (14 by 22 feet) with a number of randomly placed obstacles on the floor and pursued therein by an animal caretaker to determine whether capacity to avoid running into fixed objects was impaired. When animals were sacrificed at the end of the experiment, their eyes and approximately 15-mm lengths of the optic nerve attached thereto were removed, fixed in 10% Formalin, and processed for histopathologic study.
Reactions to both short-and long-term dosage with RC-12 alone and to short-term dosage of this agent in combination with chloroquine are summarized in Table 9 clonic in character, increased in intensity until death occurred 25 min later. The other three monkeys exhibited no outward manifestations of toxicity for 3, 5, and 9 days but became severely depressed after doses 4, 6, and 10, exhibited progressive malaise and muscular weakness thereafter, and died or were sacr-ificed in extremis on days 9, 13, and 14 after the initial dose. A dose of 200.0 mg/kg was fatal to all seven recipients. Although all of these monkeys exhibited convulsive seizures at some time during the treatment course, the duration of dosage before the first appearance of seizures varied markedly. Two monkeys began to convulse 30 min after the initial dose and were dead 15 min later. In the remaining five monkeys, convulsions first appeared after 6 to 11 doses: these seizures, lasting no more than 5 min, were followed by profound malaise and muscular weakness and death on days 8 to 12 after the initial dose.
No dose of RC-12, whether tolerated for up to 225 days or lethal, evoked changes in the formed elements of peripheral blood and bone marrow, the concentrations of glucose or urea in whole blood, alkaline phosphatase activity or bilirubin level in serum, or prothrombin time. Sublethal doses of RC-12 had no effect on body weight. Recipients of lethal doses who survived for 8 or more days suffered 5 to 9% weight losses. Doses of RC-12 ranging from 12.5 to 200.0 mg/kg were without effect on the absolute and relative (to original body weight) weights of heart, spleen, adrenals, and kidneys. Doses of 12.5, 25 .0, and 50.0 mg/kg administered daily for 225 days evoked no changes in the fundus of the eye detectable by ophthalmoscopic examination or objective evidences of loss of viscual acuity.
At doses of 50.0 mg/kg and greater, RC-12 effected both absolute and relative increases in liver size (Table 10 ). These increases were related to dose but not to the duration of dosage and were of the same order, regardless of whether RC-12 was administered as the acetate or as the NDS. The increases evoked by 50.0 mg of RC-12 per kg were neither enhanced nor diminished by concomitant dosage with chloroquine.
As indicated before, measurements of SGOT and SGPT activities were limited to the last three of the five assessments of the toxicity of RC-12. The data acquired in these appraisals showed that RC-12 in daily doses of 3.125, 6.25, 12.S, or 25.0 mg/kg for 17 to 225 days had no effect on SGOT activity but that, in daily doses of 50.0 mg/kg or greater, it produced dose-related increases in the activity of this enzyme (Table 11 , groups 1 through 5). The impacts of various doses of RC-12 on SGPT activity paralleled those on SGOT activity. For this reason, changes in SGPT activity are not detailed here.
The mean SGOT activities of recipients of doses of 50.0, 100.0, and 200.0 mg/kg were characterized by sizable standard deviations (Table 11) , implying considerable animal-toanimal variability. As indicated in the lower half of that table, the recipients of doses of both 50.0 and 100.0 mg/kg fell into two distinct families with respect to alterations in SGOT activity. Thus remaining four monkeys (group 3B), there were moderate but unequivocal elevations in SGOT activity. Similarly, in three of the eight recipients of a dose of 100.0 mg/kg (group 4A), elevations in SGOT activity were moderate; in the remaining five, they were very substantial. Persistence of elevated SGOT activity posttreatment and the possibility that such activity might become elevated in the immediate post-dosage period, when it had not been elevated before, were studied in four recipients of a dose of 50.0 mg of RC-12 NDS per kg. In two of the four monkeys, there had been no change in SGOT activity during dosage; in two, SGOT activity had increased moderately (Table 12) . SGOT activity did not change posttreatment in either niember of the former group. In both members of the latter group, activity increased substantially during the first 2 to 4 posttreatment days and then declined, reaching pretreatment levels by post-dosage day 12.
Of the organs and tissues subjected to gross and microscopic study, only the liver exhibited departures from normal that could be attributed to RC-12. The departures in this organ included an increase in size (and weight), rounding of its usually sharp edges, and a shift in color from the characteristic deep red-maroon to deep brown. With respect to both incidence and intensity, these changes were related to dose size but not to dosage duration. They were not exhibited by recipients of a dose of 12.5 or 25.0 mg/kg but were present in 12 of 20 recipients of a dose of 50.0 mg/kg for 15 to 
DISCUSSION
The studies described in this report have provided a relatively broad appraisal of the potentials of RC-12 as an antimalarial drug. Included were characterizations of (i) the capacities of this pyrocatechol derivative to control diverse phases of infections with P. cynomolgi in rhesus monkeys and (ii) its adverse effects on noninfected, otherwise normal monkeys. This group included subjects from group 3 in whom SGOT activity during treatment exceeded activity pretreatment by <50%. d This group included subjects from group 3 in whom SGOT activity during treatment exceeded activity pretreatment by >50%.
This group included subjects from group 4 in whom SGOT activity during treatment exceeded activity pretreatment by less than fourfold.
f This group included subjects from group 4 in whom SGOT activity during treatment exceeded activity pretreatment by greater than fourfold.
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Characterization of the activity of RC-12 against the early tissue forms of P. cynomolgi showed that: (i) when this agent was delivered daily throughout the incubation period in doses of 6.25 to 25.0 mg/kg it provided either nearly complete or complete protection against challenges with 105 to 106 times the minimum infective dose of sporozoites; (ii) this protective capacity was not impaired by pyrimethamine resistance; (iii) protection accorded by a fully effective regimen of 12.5 mg/kg daily for 9 days did not persist beyond the last dosage day but could be extended by 6 days when the size of the daily dose was increased fourfold; and (iv) once-weekly doses provided protection only when delivered on the day of sporozoite challenge and even then was complete in only 40% of the applications.
Characterization of the activity of RC-12 against the developed and persisting tissue forms of P. cynomnolgi showed that: (i) these forms could be eradicated, resulting in radical cure, by essentially the same daily doses required for protection against infections with sporozoites; (ii) because of the limited activity of RC-12 against the erythrocytic stages of the parasite, cure of established infections required concomitant dosage with an effective blood schizonticide, such as chloroquine; and (iii) the developed and persisting tissue forms could be eradicated by a dosage regimen as brief as 4 days.
Characterization of the activity of RC-12 against the erythrocytic stage of infections, although limited in scope, showed that: (i) parasitemia could be reduced to thick-bloodfilm-negative levels by daily doses of 6.25 mg/kg, but that the blood schizonts could not be eliminated completely by doses as large as 100.0 mg/kg; (ii) the time from first dose of RC-12 to reduction of parasitemia to thick-blood-film-negative status was independent of the size of the dose, within the above range; and (iii) the times required for such reduction in recrudescences were either the same or slightly shorter than those required on initial treatment, suggesting that parasites responsible for recrudescences were not resistant to Characterization of the subacute toxicity of RC-12 for the rhesus monkey showed that: (i) daily doses of 50.0 mg/kg or lower for 15 to 225 days evoked no outward manifestations of toxicity; (ii) doses of 100.0 and 200.0 mg/kg evoked fatal reactions referrable to central nervous system stimulation and depression; (iii) time between delivery of the first of the above doses and occurrence of fatal reactions was highly variable, from 45 min after the initial dose to 23 h after dose 11 in the recipients of 200.0 mg/kg; (iv) doses of 25 .0 mg/kg and less for 15 to 225 days produced no discrete toxic reactions; (v) repetitive doses of 50.0 to 100.0 mg/kg produced hepatomegaly, elevations in the activities of transaminases in serum, and vacuolation of hepatocytes: (vi) the intensity of these manifestations of hepatotoxicity was dose related; (vii) the elevations in transaminase activities in recipients of a dose of 50.0 mg/kg did not increase with protracted dosage and were promptly reversible upon termination of the treatment; and (viii) concomitant administration of chloroquine did not affect the incidence or intensity of either overt or discrete manifestations of RC-12 toxicity.
Studies on the absorption, elimination, tissue disposition, and metabolic fate of RC-12 were included in the original plans for assessing the potential of this agent as an antimalarial drug. Their omission from this report, a significant shortcoming, stems from our inability to develop an acceptable analytical procedure during the 3-year period when RC-12 was under study. Efforts to apply methyl orange coupling (3) and induced fluorescence (4, 8, 46) procedures were unsuccessful, as was a method based on the reaction of RC-12 with trans-aconitic acid, made available to us in early 1967 (personal communication, R. Strufe, Institut fur Parasitologie und Veterinarmedizin, Farbenfabriken Bayer AG, 13 February 1967) . This procedure worked well with pure solutions of RC-12 but was unreliable when applied to either spiked body fluids and tissue homogenates from normal monkeys or fluids and tissue homogenates from recipients of RC-12. If further studies on RC-12 are undertaken, especially those for tolerability and activity against the malarias in humans, they should be preceded by assessments of the pharmacokinetics of this compound. This effort could doubtless be served effectively by tools not available to us at the time of our studies, such as, for example, gas-liquid and high-pressure liquid chromatography and radioisotopic labeling of RC-12 at specific sites.
A preliminary report (40) The preliminary report referred to previously also led to three investigations of the capacity of RC-12 to prevent malarial infections in mice. In one study (27) , a dose of 400 mg/kg administered subcutaneously in an oleaginous vehicle provided protection at an unspecified level against infections with sporozoites of the 17X strain of Plasnioduium be,g/li ioelii. In a second study (9) (34) , which since 1954 has been used widely and successfully for radical cure of infections with P. i'iavx (1) and less widely and successfully for prevention of infections with this plasmodium and P. fiilciparmln (13, 25, 44 (22, 23) .
Measured by size of dose required for the same level of accomplishment, RC-12 is much less active than primaquine.
In a 9-day prophylactic regimen, the daily doses of RC-12 and primaquine required to protect 50%, of the inoculees (PDs)) and the 95%, confidence limits of these PD)(s (17) were 5.6 (4.5 to 7.0) and 0.5 (0.38 to 0.63) mg/kg, respectively. In a 14-day curative regimen, the daily dose of RC-12 required to eradicate 50% of established infections (CDs0) and the 95% confidence limits of this CD,( (17) (2, 34) , most of which were evident in recipients of one-eighth of the lethal dose, but became more intense as the dose was increased to the lethal level. These reactions included abdominal cramping, malaise, methemoglobinemia, anemia, reticulocytopenia, leukopenia with granulocytopenia, general suppression of bone marrow activity, and progressive manifestations of hepatotoxicity, including bilirubinemia, with widespread central lobular necrosis of the liver as a terminal event.
Relating the PDs(s and CD5(s of RC-12 and primaquine to the LD5(s as LD5(/PD5( and LD5(/CDs( produces a form of therapeutic index which suggests that there is little to choose between the potentials of these agents for prophylaxis or radical cure. The LD5(/PD5( indexes were approximately 20 for both agents. The LD(0/CD(0 indexes were ca. 17 for RC-12 and 26 for primaquine.
The above assessment implies that RC-12 might come close to being a match for primaquine but could not be considered superior to this 8-aminoquinoline. This notwithstanding, the investigators at the Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, whose early interests in RC-12 had led to major studies on the properties of RC-12 NDS, were still interested in evaluating this pyrocatechol derivative for tolerability and antimalarial activities in human volunteers. There were at least three reasons for their continuing interest. First, RC-12 was the only non-8-aminoquinoline evaluated for activity against P. (cnloln()/gi infections in rhesus monkeys over a period of 20 years that had the capacity to prevent infections and effect radical cure (40) . Second, RC-12 evoked a narrower spectrum of toxic reactions than did primaquine, and these reactions to RC-12 were characterized by steeper dose-response curves. Third, since RC-12 appeared to be free of hematotoxicity, it seemed likely that its application, unlike that of primaquine, would present no special hazard to recipients with glucose-6-phosphate dehydrogenase defi-VOL. 28. 1985 on November 6, 2017 by guest http://aac.asm.org/ Downloaded from ANTIMICROB. AGENTS CHEMOTHER.
ciency. Accordingly, plans were made in late 1967 for evaluating the toxicity and prophylactic and radical curative activities of RC-12 in prisoner volunteers at the U.S. Penitentiary, Atlanta, Ga., and submitted to the National Institutes of Health review group that was responsible for approval of trials of new agents in humans. The proposed study was disapproved, reportedly because primaquine met identifiable needs for prophylaxis and radical cure of infections with P. vivax so effectively that commitment of human volunteers to evaluations of an agent comparable to this 8-arninoquinoline with respect to scope of activity and efficacy could not be justified.
Some 6 years later, concerns with the performance of primaquine in Vietnam (32) led those responsible for the U.S. Army Malaria Research Program to sponsor limited appraisals in human volunteers of the tolerability of RC-12 and its capacities to protect against infections with sporozoites of the Chesson strain of P. vivax and cure established infections with this strain (6) . The largest dose of RC-12 administered, 10.0 mg/kg daily for 7 days, comparable to that which regularly protected against and cured infections with P. cynomolgi, was fully tolerated. Application of this dose in a conventional prophylactic regimen neither prevented infections nor delayed their onset in three of three volunteers, nor did it cure established infections in two of two volunteers when administered concomitantly with chloroquine.
To some, the failure of RC-12 to prevent or cure infections with P. vivax when administered in a dose very close to that which regularly prevents and cures infections with P. cynomolgi sufficed to end interest in this agent and the chemical family to which it belongs (5, 24). Our reaction is somewhat different. RC-12 is unique among non-8-aminoquinolines with respect to providing complete protection against and effecting cure of infections with P. cynomolgi at welltolerated doses and interrupting the sporogonic cycle. To this point, the performances of test compounds against infections with this simian plasmodium and those against infections with the Chesson strain of P. vivax have been essentially identical. In view of this, it would seem premature to place RC-12 in the category of inactive antimalarial agents without first determining whether the dichotomy between the activities exhibited against infections with P. vivax and P. cynomolgi rests on differences in physiological disposition in humans and rhesus monkeys. The inactivity of RC-12 against infections with P. vivax might be due to poor absorption of the compound when administered as the naphthalenedisulfonate, uncommonly rapid renal clearance, speedy conversion of absorbed compound to an inactive metabolite, failure to convert the parent agent to an active metabolite, or poor localization of parent compound or active metabolite in the liver. Attention to such parameters might point the way to effective application of RC412 per se or its metabolites, or even an appropriately designed congener, against infections with P. vivax. At the least it should insure against premature shelving of interest in the pyrocatechols comparable to that which occurred in 1929 after inappropriate evaluation of the activity of Dimeplasmin, a close structural relative of RC-12 (40) .
Finally, identification of the factor(s) responsible for the negative performance of RC-12 against infections with P. vivax is of special importance to the continuing use of infections with P. cynoiniolgi in the search for more effective and generally useful tissue schizonticides. This use dates from 1948, when it was shown that infections with sporozoites of this simian plasmodium in rhesus monkeys and those of the Chesson strain of P. vivax in human volunteers responded in an essentially identical manner to such drugs as quinine, chloroquine and other 4-aminoquinolines, chlorguanide, pamaquine, pentaquine, isopentaquine, and primaquine (36) . Since that time, 201 8-aminoquinolines and 187 non-8-aminoquinolines have been evaluated for activity against infections with P. cynomolgi (31, 32) , with the assumption that the results of these assessments carried over to infections with P. vivax. Unless the dichotomy between the activities of RC-12 can be explained, confidence in the predictive value of results acquired in the simian infection must be qualified. Prompt resolution of this dichotomy is a matter of considerable urgency for, because of current obstacles to pursuing studies in human volunteers, even greater reliance must be placed on results obtained in lower animal test systems if the search for better tissue schizonticidal drugs is to be pursued productively.
